Tff Pharmaceuticals Inc (TFFP) concluded trading on Thursday at a closing price of $0.06, with 10.97 million shares of worth about $0.66 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -96.60% during that period and on December 12, 2024 the price saw a loss of about -60.05%. Currently the company’s common shares owned by public are about 4.44M shares, out of which, 4.08M shares are available for trading.
Stock saw a price change of -78.90% in past 5 days and over the past one month there was a price change of -96.41%. Year-to-date (YTD), TFFP shares are showing a performance of -99.07% which decreased to -99.21% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.16 but also hit the highest price of $11.00 during that period. The average intraday trading volume for Tff Pharmaceuticals Inc shares is 1.43 million. The stock is currently trading -82.50% below its 20-day simple moving average (SMA20), while that difference is down -95.27% for SMA50 and it goes to -97.52% lower than SMA200.
Tff Pharmaceuticals Inc (NASDAQ: TFFP) currently have 4.44M outstanding shares and institutions hold larger chunk of about 12.80% of that.
The stock has a current market capitalization of $0.29M and its 3Y-monthly beta is at 1.07. It has posted earnings per share of -$6.45 in the same period. It has Quick Ratio of 0.89 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TFFP, volatility over the week remained 23.57% while standing at 24.88% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on May 19, 2022 offering a Buy rating for the stock and assigned a target price of $22 to it. Coverage by H.C. Wainwright stated Tff Pharmaceuticals Inc (TFFP) stock as a Buy in their note to investors on February 08, 2021, suggesting a price target of $31 for the stock. On December 07, 2020, B. Riley Securities Initiated their recommendations, while on August 17, 2020, Maxim Group Reiterated their ratings for the stock with a price target of $18. Stock get a Buy rating from Maxim Group on July 08, 2020.
